Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percent of financing that must be repaid to discontinue the revenue sharing provisions of product financing.

+ References

No definition available.

+ Details

Name:	wint_FinancingOfProductPercentOfFinancingThatMustBeRepaidToDiscontinueRevenueSharing
Namespace Prefix:	wint_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The percent of revenue shared with financer for the financing of a product.

+ References

No definition available.

+ Details

Name:	wint_FinancingOfProductPercentOfRevenueSharedWithFinancer
Namespace Prefix:	wint_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents maximum amounts of payments maybe received based on potential milestone achievement.

+ References

No definition available.

+ Details

Name:	wint_MaximumAmountMayBeReceivedForPotentialMilestonePayments
Namespace Prefix:	wint_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum amount that may be received for sales milestone payments.

+ References

No definition available.

+ Details

Name:	wint_MaximumAmountMayBeReceivedForSalesMilestonePayments
Namespace Prefix:	wint_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum amount of finance to be received regarding the amount of nonrefundable payments pursuant to the agreement, that satisfy the special circumstances.

+ References

No definition available.

+ Details

Name:	wint_NonrefundablePaymentsMaximumFinancingToBeReceivedUnderSpecialCircumstances
Namespace Prefix:	wint_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of cash inflow from payments from a third party to develop a product.

+ References

No definition available.

+ Details

Name:	wint_ProceedsForPaymentsToDevelopProduct
Namespace Prefix:	wint_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period after the first commercial sale for royalties to be received.

+ References

No definition available.

+ Details

Name:	wint_RoyaltiesToBeReceivedPeriodAfterFirstCommercialSale
Namespace Prefix:	wint_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of reduction of royalty rates.

+ References

No definition available.

+ Details

Name:	wint_RoyaltyRateReductionPercentage
Namespace Prefix:	wint_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=wint_AerosurfFundingTermSheetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=wint_LeesPharmaceuticalHoldingsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=wint_TermSheetWithLeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=wint_ARLicenseAgreementWithLeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=wint_LicenseAgreementWithLeesPharmaceuticalHkLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Note 11 - Licensing and Research Funding Agreements (Details Textual) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 12, 2024	Jun. 30, 2019	Dec. 31, 2021	Dec. 31, 2022	Aug. 17, 2022	Sep. 30, 2020	Mar. 18, 2020
AEROSURF Funding Term Sheet [Member] \| Lee’s Pharmaceutical Holdings Limited [Member]
Nonrefundable Payments, Maximum Financing to Be Received Under Special Circumstances						$ 2,800
Term Sheet With Lee [Member]
Proceeds for Payments to Develop Product			$ 1,000
Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing							125.00%
Financing of Product, Percent of Revenue Shared With Financer							50.00%
Term Sheet With Lee [Member] \| Other Liabilities [Member]
Contractual Obligation, Total				$ 3,800
A&R License Agreement With Lee [Member]
Proceeds for Payments to Develop Product		$ 1,000
Maximum Amount May be Received for Potential Milestone Payments					$ 78,900
License Agreement with Lee’s Pharmaceutical (HK) Ltd. [Member]
Maximum Amount May be Received for Potential Milestone Payments	$ 3,100
Maximum Amount May be Received for Sales Milestone Payments	$ 135,250
Royalties to be Received, Period After First Commercial Sale (Year)	10 years
Royalty Rate Reduction Percentage	50.00%